Armata Pharmaceuticals, Inc. — Earnings Release 2016

Mar 31, 2016

8-K 1 v435653_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 30, 2016

Commission File Number: 001-37544

AmpliPhi Biosciences Corporation

(Exact name of Registrant as specified in its charter)

Washington	91-1549568
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

3579 Valley Centre Drive

San Diego, California 92130

(Address of principal executive offices)

804-827-2524

(Registrant’s Telephone number)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Field: Page; Sequence: 1

Field: /Page

Item 2.02 Results of Operations and Financial Condition.

On March 30, 2016, we announced our financial results for the full year ended December 31, 2015 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. As previously announced, we also held a conference call on March 30, 2016 to discuss these financial results. An excerpt of the conference call transcript is attached hereto as Exhibit 99.2 and incorporated herein by reference.

The information in this Item 2.02 and the attached Exhibits 99.1 and 99.2 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached exhibits shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release issued by AmpliPhi Biosciences Corporation on March 30, 2016 relating to financial results
99.2	Excerpt of transcript from conference call held on March 30, 2016 relating to financial results.

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 31, 2016
By:	/s/ Steve R. Martin
Name:	Steve R. Martin
Title:	Chief Financial Officer

Field: Page; Sequence: 3

Field: /Page

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release issued by AmpliPhi Biosciences Corporation on March 30, 2016 relating to financial results
99.2	Excerpt of transcript from conference call held on March 30, 2016 relating to financial results.

Field: Page; Sequence: 4; Options: Last

Field: /Page